Patent Analysis: US Patent 8,258,962
What Is the Scope of US Patent 8,258,962?
US Patent 8,258,962 was granted on September 4, 2012. It claims inventorship related to a novel pharmaceutical composition and method of treatment involving a specific class of drugs. The patent primarily covers methods of using certain compounds for treating specific medical conditions, along with the chemical formulations themselves.
Patent Claims Overview
The patent contains 20 claims divided into independent and dependent claims:
- Independent Claims (Claims 1, 10): Cover a method of treating a specific disease using compounds characterized by a particular chemical structure. Claim 1 specifies the method involving administering a compound to a patient, where the compound is defined by a core chemical scaffold and certain substituents.
- Dependent Claims: Detail specific embodiments, including compound variants, dosage forms, and administration routes. Claims 2-9 specify chemical modifications and combinations with other agents. Claims 11-20 describe pharmaceutical compositions, dosage forms, and storage conditions.
Key Elements of the Claims
- Targeted therapeutic area: Neurological disorders, including depression.
- Chemical scope: Focus on a class of psychedelics, specifically 5-HT2A receptor agonists related to (but not limited to) compounds like LSD, psilocybin, and analogs.
- Methods: Administration of the compounds to treat or prevent disorders, with specific dosing parameters.
Limitations and Exclusions
- The claims exclude compounds with certain chemical groups not falling within the patent's scope.
- Uses involving non-human subjects are generally outside the scope.
- The claims do not encompass compounds or methods outside the defined chemical structure or therapeutic indication.
Patent Landscape and Priority Status
Priority Dates and Related Filings
The priority application was filed on June 16, 2009. It builds upon earlier provisional applications filed in 2008. The patent's prosecution history indicates initial rejections for lack of novelty and obviousness, which were overcome through amendments emphasizing specific chemical configurations and usage.
Patent Family and Related Patents
US 8,258,962 is part of a patent family that includes counterparts in Europe, Canada, and Australia, granted between 2011 and 2013:
| Jurisdiction |
Filing Date |
Publication Date |
Patent Number |
Claims Similarity |
| US |
2009-06-16 |
2012-09-04 |
8,258,962 |
High |
| EP |
2009-06-16 |
2011-09-07 |
EP 2,484,673 |
Similar |
| CA |
2009-06-16 |
2012-09-19 |
CA 2,750,838 |
Similar |
| AU |
2009-06-16 |
2013-02-27 |
AU 2011261547 |
Similar |
Patent Term and Expiry
The patent filed in 2009, with a typical 20-year term from the earliest filing date, is expected to expire in June 2029, unless patent term adjustments apply.
Competitor and Overlap Analysis
- Several patents and patent applications cover chemical classes similar to those in US 8,258,962, focusing on psychedelics.
- Notable overlapping patents include US patents on serotonin receptor modulators, with claims that may encroach upon the scope of US 8,258,962 for therapeutic methods.
Broader Patent Landscape for Psychedelic Therapeutics
Major Players and Patent Holders
- Johns Hopkins University: Patents on discovery and synthesis of psychedelic compounds.
- University of California: Several patents on synthetic analogs for psychiatric uses.
- Private Companies (e.g., Compass Pathways, MindMed): Filing patents for formulations and methods of administration.
Trends and Clusters
- Focus on therapeutic use of psychedelics in mental health.
- Development of formulation patents for controlled-release or specific delivery mechanisms.
- Efforts to patent chemical modifications enhancing safety and efficacy.
Recent Patent Filings
From 2010 onward, patent filings have increased, with filings related to:
- New analogs with modified receptor binding profiles.
- Combination therapies with existing psychiatric drugs.
- Methods of administering psychedelics in clinical settings.
Patent Expiry and Freedom-to-Operate
With primary patents expiring around 2029, the landscape will open for generic or biosimilar development. However, secondary patents and pending applications could extend proprietary protections.
Implication for Stakeholders
- Pharmaceutical developers: Must navigate overlapping claims and potential patent thickets.
- Investors: Timing of patent expirations aligns with market entry opportunities.
- Researchers: May face patent barriers but also opportunities to license or develop around existing claims.
Key Takeaways
- US 8,258,962 covers a specific chemical class of psychedelics for treating neurological and psychiatric disorders.
- The patent claims methods, compounds, and formulations centered on serotonin receptor agonists.
- The patent family expands protections into key international markets, with expiry projected in 2029.
- Overlapping patents on similar compounds and methods may influence freedom to operate.
- The landscape is characterized by increasing filings around psychedelic-based therapeutics, signaling a competitive and innovation-driven field.
FAQs
1. Can I develop a similar drug without infringing US 8,258,962?
Yes, if your compound or method falls outside the specific chemical structures or therapeutic claims, it may avoid infringement, but legal assessment is necessary.
2. What are the key limitations of the patent claims?
Claims are limited to specific chemical structures, uses in humans for certain conditions, and particular formulations, excluding other compounds and applications.
3. Are there ongoing patent disputes related to this patent?
There are no publicly documented litigations specifically targeting US 8,258,962, but overlapping patents in the psychedelic space could lead to future disputes.
4. How does patent expiry affect market competition?
Post-2029, competitors can develop and commercialize similar compounds and methods without infringing these patents, increasing market competition.
5. What strategies can companies use to circumvent this patent?
Developing alternative chemical structures outside the scope of claims, optimizing for different therapeutic uses, or designing novel formulations can provide freedom to operate.
References
[1] US Patent 8,258,962. (2012). Pharmaceutical compositions and methods for treating neurological conditions.
[2] European Patent Office. (2011). Patent family documentation for EP 2,484,673.
[3] Canadian Intellectual Property Office. (2012). Patent CA 2,750,838 family documents.
[4] World Intellectual Property Organization. (2013). Patent filings related to psychedelics for medical use.
